Perfuze, a Galway, Ireland-based medical device company developing next-generation catheter-based technology to treat acute ischemic stroke, closed a €3m seed funding round.
The round was led by Earlybird, investing from its Health Tech Fund, joined by MedFocus, investing from its HBM-MedFocus Fund. Other investors include Enterprise Ireland and a syndicate of Irish medical device sector veterans and stroke physicians.
The company intends to use the funds forthe further development of the Millipede platform technology.
Founded in 2018 by Wayne Allen and Liam Mullins, Perfuze is developing innovative catheter technology to treat acute ischemic stroke.
The company is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
FinSMEs
29/01/2019